Abstract

NOVEL DRUG DELIVERY AND DRUG TARGETING RECOMBINANT HUMAN ERYTHROPOETIN TO TREAT ANEMIA

Made Prita Artika*, Sirilus Deodatus Sawu, Ruliya Yunita Effendy, Aditya Nugaraha and Dini Aprilia

.

Abstract

Recombinant Human erythropoietin (RhEpo) has become an important discovery in the medical world related to biological products. The discovery of RhEpo is very helpful in handling anemia conditions that caused by CKD, cancer patients undergoing chemotherapy, HIV and patient who lose a lot of blood after surgery. Anemia condition make the body cannot produce normally endogenus erythropoietin. Erythropoietin helps in proliferation, differentiation and maturation so they can increase of normal red blood cells. The erythropoietin gene was isolated and produced known as Recombinant Erythropoietin. RhEpo has poor stability so the administration still uses the parenteral route to preventing aggregation and denaturation. Other developments still carried out to optimization the gene of human erythroid cells. This could be an apportunity for find targets, drug selection and use of gene therapy for several diseases related to another blood disorders. Knowledge regarding the use of RhEpo will be very helpful to optimization of therapeutic effects.

Keywords: Erythropoetin, RhEpo, Anemia.